Becton, Dickinson and Company (NYSE:BDX) Stock Position Decreased by Wedmont Private Capital

Wedmont Private Capital lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 44.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 884 shares of the medical instruments supplier’s stock after selling 714 shares during the quarter. Wedmont Private Capital’s holdings in Becton, Dickinson and were worth $218,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of BDX. Icapital Wealth LLC bought a new stake in shares of Becton, Dickinson and during the 1st quarter valued at about $31,000. Disciplined Investments LLC bought a new position in Becton, Dickinson and in the 1st quarter worth about $32,000. Rosenberg Matthew Hamilton grew its position in Becton, Dickinson and by 61.5% in the 1st quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 48 shares during the last quarter. Core Alternative Capital grew its position in Becton, Dickinson and by 688.2% in the 1st quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 117 shares during the last quarter. Finally, EverSource Wealth Advisors LLC bought a new position in Becton, Dickinson and in the 4th quarter worth about $38,000. Institutional investors own 86.74% of the company’s stock.

Insider Activity at Becton, Dickinson and

In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the sale, the chief executive officer now directly owns 28,878 shares of the company’s stock, valued at $7,656,424.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Samrat S. Khichi sold 9,185 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total value of $2,392,141.40. Following the completion of the transaction, the executive vice president now owns 5,928 shares of the company’s stock, valued at approximately $1,543,888.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas E. Polen, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the transaction, the chief executive officer now directly owns 28,878 shares of the company’s stock, valued at approximately $7,656,424.14. The disclosure for this sale can be found here. Insiders sold a total of 19,160 shares of company stock valued at $5,036,751 over the last ninety days. Insiders own 0.50% of the company’s stock.

Becton, Dickinson and Trading Down 2.8 %

Shares of NYSE:BDX opened at $244.11 on Wednesday. The company has a 50 day moving average of $252.11 and a 200-day moving average of $254.39. The firm has a market cap of $69.62 billion, a P/E ratio of 42.09, a P/E/G ratio of 3.33 and a beta of 0.57. Becton, Dickinson and Company has a twelve month low of $231.46 and a twelve month high of $280.62. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58.

Becton, Dickinson and (NYSE:BDXGet Rating) last released its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business had revenue of $4.64 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same period in the prior year, the business earned $2.74 earnings per share. The business’s quarterly revenue was down 5.1% on a year-over-year basis. As a group, analysts anticipate that Becton, Dickinson and Company will post 11.31 earnings per share for the current fiscal year.

Becton, Dickinson and Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be paid a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.43%. The ex-dividend date of this dividend is Thursday, September 8th. Becton, Dickinson and’s dividend payout ratio is presently 60.00%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Morgan Stanley decreased their target price on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a research report on Friday, June 24th. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $265.00 to $235.00 in a research report on Monday, July 11th. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Saturday, September 10th. Finally, Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and from $290.00 to $280.00 in a research note on Monday, July 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and has a consensus rating of “Hold” and a consensus price target of $277.63.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.